DoJ Targets Device Labeling Accuracy In $300 Million Quest Settlement
This article was originally published in The Gray Sheet
Executive Summary
A $302 million settlement between Quest Diagnostics and the Department of Justice announced April 15 suggests DoJ will go after device firms for knowingly misrepresenting product information in labeling and marketing materials, even if FDA is not actively investigating the matter
You may also be interested in...
DOJ Prosecutors Turn Attention To Manufacturing, Safety Issues
The Department of Justice is increasingly tackling issues of FDA compliance beyond the standard sales and marketing fare, pursuing cases related to device manufacturing, adverse event reporting and even product labeling, recent cases suggest
DOJ Prosecutors Turn Attention To Manufacturing, Safety Issues
The Department of Justice is increasingly tackling issues of FDA compliance beyond the standard sales and marketing fare, pursuing cases related to device manufacturing, adverse event reporting and even product labeling, recent cases suggest
Device Companies Urge Whistleblowers To Air Complaints In-House
Device companies are trying to encourage employees to report suspected fraud internally rather than going straight to government authorities - with limited success to date